Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.
نویسندگان
چکیده
potasio en el colon. El mecanismo a través del cual se aumenta la secreción colónica de potasio en estos pacientes es complejo; y depende de varios factores. Por un lado, existe un aumento de la actividad de la bomba Na+/K+ ATPasa en la membrana basolateral de la célula intestinal, que conlleva a un aumento de la concentración de potasio intracelular y a un aumento en la conductividad del potasio en células apicales. La secreción de potasio del colon también está aumentada por la aldosterona, y aunque su mecanismo no está del todo descrito, parece tener relación con un aumento en la expresión de los canales de alta conductividad del potasio (BK channels) en la membrana apical de la célula intestinal3. Konowa et al., publicaron un caso4 en el año 2013, en el cual se describe una paciente con IRCT en programa de hemodiálisis que se somete a resección de la unión íleo-cecal y una ileostomía temporal, tras lo cual la paciente desarrolla una hiperpotasemia, que revierte tras la reanastomosis del colon. Diversos estudios in vitro e in vivo, han demostrado con técnicas de inmunohistoquímica que existe una mayor expresión de los BK channels en pacientes con IRCT, que en aquellos pacientes con función renal normal; en los que predomina la expresión de canales de baja o mediana conductividad de potasio. En resumen, la secreción de potasio en el tracto gastrointestinal es un mecanismo complejo y fundamental para mantener la homeostasis del mismo en pacientes con IRCT. Nuestro caso demuestra la importancia de la secreción de potasio en el colon en pacientes con IRCT. b i b l i o g r a f í a
منابع مشابه
Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease.
Denosumab has been approved for the prevention of skeletal-related events of bone metastases (120 mg at every 4 weeks) and for the treatment of osteoporosis (60 mg at every 6 months). Post-denosumab hypocalcemia occurred in 5.2% of the cancer patients (1), but such an event was rarely reported in osteoporosis patients (2). Recently, severe hypocalcemia because of a lower dose of denosumab for o...
متن کاملSevere hypocalcemia following a single injection of denosumab in a patient with renal impairment
Monitoring renal function and adjusting dosing for patients with impaired renal function are not required with denosumab (60 mg every 6 months). However, these patients have an increased risk for developing hypocalcemia. This case report describes a patient with renal impairment who developed severe hypocalcemia after receiving denosumab.
متن کاملDenosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
Denosumab is a human monoclonal antibody representing a novel therapy of osteoporosis. Contrary to always other antiosteoporotic drugs, it is not contraindicated in advanced chronic kidney disease, as its pharmacokinetic does not differ from patients with normal kidney function. However, published case reports in chronic kidney disease (CKD) patients stopped the therapy after single dose becaus...
متن کاملSevere Hypocalcemia due to Denosumab in Metastatic Prostate Cancer
Denosumab is a monoclonal antibody used for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Hypocalcemia is a rare and dangerous side effect of the drug Denosumab. We present a case of a patient with metastatic prostate cancer who developed severe hypocalcemia after the administration of the drug. The patient's vitamin D levels were low when chec...
متن کاملRisk Factors for Hypocalcemia following Treatment with Denosumab in Patients with Bone Metastases from Prostate Cancer
Objective: To evaluate risk factors for Denosumab-induced hypocalcemia in prostate cancer patients with bone metastases. Methods: In this single-arm, open-label, prospective multicenter study, 48 prostate cancer patients with bone metastases received Denosumab (120 mg on day 1) and androgen-deprivation therapy. Serum calcium, albumin, alkaline phosphatase (ALP), and phosphate levels; chronic ki...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
دوره 38 1 شماره
صفحات -
تاریخ انتشار 2018